https://www.marketscreener.com/quote/stock/IGNYTA-INC-16023295/news/Ignyta-Receives-European-Medicines-Agency-Prime-Designation-for-Entrectinib-in-NTRK-Fusion-Positiv-25299714/?utm_source=telegram&utm_medium=social&utm_campaign=share